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Abstract 
 
Key points and main messages of the new (2018) American 
Guidelines on cholesterol management are herein provided with 
tabulation of the risk assessment tools, the classification of 
statins according to their therapeutic intensity and desired lipid 
levels in children. Rhythmos 2019;14(1):1-4. 
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The new (2018) American guidelines on 
cholesterol management provide a more personalized 
approach in risk assessment (Tables 1 & 2) and the 
decision to start therapy, with new options for those of very 
high-risk for atherosclerotic cardiovascular (CV) disease 
(CVD), while they have returned to the use of low-density 
lipoprotein (LDL)-cholesterol level targets.1 These 
guidelines also put emphasis on lifestyle modification and 
shared decision-making. They discuss the value of using 
coronary artery calcium (CAC) scores for some patients 
(some consider this excessively costly), the importance of 
considering family history for risk calculation, the effect 
of age (<40 and >75) on the CV risk (considering it 
appropriate to treat older people). The level of LDL 
cholesterol >160 mg/dl is considered “very high”; a level 
of <100 mg/dl is considered to be associated with lower 
CV risk, but for high risk patients the level that should be 
attained is <70 mg/dl. The guidelines also cover the 
pediatric population. Children of very high-risk families 
can be tested as early as at the age of 2. However, for the 
majority of children, the recommendation is to have an 
initial test between ages 9 and 11, and then a follow-up test 
between the ages of 17 and 21.  
 
An aggressive approach is recommended for 
individuals who have atherosclerotic CVD, a very high 
cholesterol level, or diabetes mellitus (DM). In these 
groups, in addition to a healthy lifestyle, a statin is 
recommended, if tolerated, and, when needed, additional 
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medications, depending on the LDL-cholesterol level. The 
guidelines encourage increased collaboration between 
physicians and their patients (participatory medicine / 
shared decision-making) that will include discussion of 
risk-enhancing factors (Table 2).  
 
Table 1. Variables in risk assessment tools  
 
• Age • Sex • Race • Total cholesterol • HDL-cholesterol   
• Systolic BP • Antihypertensive therapy • History of 
diabetes mellitus • Current smoking • hsCRP level  
• Parental history of MI before age 60  
_______________________________________________________________  
BP = blood pressure; HDL = high-density lipoprotein; hsCRP = high-
sensitivity C-reactive protein; MI = myocardial infarction 
 
 For primary prevention, atherosclerotic CVD risk 
factors should be sought. One major CVD risk factor is 
elevated measured serum LDL-cholesterol. Screening can 
be performed with fasting or nonfasting measurement of 
lipids. In children, adolescents (10-19 years of age), and 
young adults (20-39 years of age), priority should be given 
to estimation of lifetime risk and promotion of healthy 
lifestyle. Drug therapy is needed only in selected patients 
with moderately high (≥160 mg/dL) or very high LDL-
cholesterol levels (>190 mg/dL). Three major higher-risk 
categories are patients with severe hypercholesterolemia 
(LDL-cholesterol levels ≥190 mg/dL), adults with DM, 
and adults 40 - 75 years of age, who are candidates for 
immediate statin therapy without further risk assessment. 
 
Table 2. Risk-enhancing factors 
 
• Family history of premature atherosclerotic CVD (men: <55 y, 
women: <65 y) 
• Primary hypercholesterolemia (LDL-cholesterol, 160–189 
mg/dL; non–HDL-cholesterol 190–219 mg/dL)   
• Metabolic syndrome 
• Chronic kidney disease (eGFR <60 mL/min/1.73 m2) 
• Chronic inflammatory disease (e.g. psoriasis, rheumatoid 
arthritis, or HIV/AIDS  
• History of premature menopause (<40 y) or pregnancy-
associated conditions that increase later CVD risk such as 
preeclampsia 
• High-risk race/ethnicities (e.g., South Asian ancestry) 
 
• Lipid/biomarkers 
• Persistently ↑ triglycerides (≥175 mg/dL); o if measured:   
• ↑ hsCRP (≥2.0 mg/L)  
• ↑ Lp(a): ≥50 mg/dL or ≥125 nmol/L  
• ↑ apoB ≥130 mg/dL:  
• ABI <0.9  
_______________________________________________________________ 
ABI = ankle-brachial index AIDS = acquired immunodeficiency 
syndrome; ABI, apoB = apolipoprotein B; CVD = cardiovascular 
disease; eGFR = estimated glomerular filtration rate; hsCRP = high-
sensitivity C-reactive protein; Lp(a)= lipoprotein (a) 
 
Main Messages 
 Some of the main messages are herein outlined:  
1. A heart-healthy lifestyle with healthy diet and regular 
physical activity is emphasized for all ages.  
 
2. Use of high-intensity statin therapy (Table 3) at 
maximal tolerated doses is recommended in patients with 
clinical atherosclerotic CVD to lower LDL cholesterol by 
≥50%. 
 
3. Cholesterol targets return: for very high-risk CVD 
patients (history of multiple major CVD events or 1 major 
CVD event and multiple high-risk conditions), the target 
for LDL-cholesterol should be < 70 mg/dL.  
 
4. A stepped approach is recommended: when the 
desired target is not achieved with a statin, addition of 
non-statins to statin therapy may be considered.  
 
4a. Non-statins to add comprise oral ezetimibe (prevents 
the absorption of cholesterol in the intestine) or injectable 
PCSK9 inhibitor 2  
 
5. In patients at very high risk whose LDL-cholesterol 
level remains ≥70 mg/dL on maximally tolerated statin and 
ezetimibe therapy, adding a PCSK9 inhibitor is reasonable, 
although the long-term safety (>3 years) is uncertain and 
cost-effectiveness is currently low  
 
6. In patients with LDL-cholesterol ≥190 mg/dL, high-
intensity statin therapy should be started without 
bothering to calculate 10-year CVD risk. However, in 
this group, the target is <100 mg/dL instead of <70 mg/dL, 
probably because there is no evidence, yet, of actual 
atherosclerosis.  
 
6a. If the LDL-cholesterol remains ≥100 mg/dL, adding 
ezetimibe is reasonable.  
 
6b. If the LDL-cholesterol remains ≥100 mg/dL despite 
statin plus ezetimibe therapy and the patient has multiple 
factors that increase subsequent risk of CVD events, a 
PCSK9 inhibitor may be considered, with the caveats of 
uncertain long-term safety (>3 years) and high cost of this 
therapy. 
 
7. In patients 40 - 75 years of age with DM and LDL-
cholesterol ≥70 mg/dL, moderate-intensity statin therapy 
should be used; high-intensity statin therapy should be 
used in those at higher risk (multiple risk factors or age 
50-75 years) 
 
In the group of healthy people with moderately 
elevated cholesterol levels, the decision to start a statin 
will depend on the presence of other CV risk factors, 
such as smoking, hypertension, DM, family history of 
premature atherosclerotic CVD, and the LDL-cholesterol 
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level; other factors might comprise ethnicity (e.g. South 
Asian ethnicity) or premature menopause (before age 40), 
metabolic syndrome, elevated triglycerides or elevated 
high-sensitivity C-reactive protein levels (a marker of 
inflammation), might also direct towards starting someone 
on a statin. Finally, the guidelines have included coronary 
artery calcium (CAC) as determined by (simplified) CT 
scan as a tool to decide about the initiation of statin therapy 
in certain cases.3 Patient preferences and cost (though most 
statins are now generic) need also be considered. Online 
risk calculators may be helpful. 
 
8. In adults 40-75 years of age evaluated for primary 
CVD prevention, a physician–patient risk discussion 
should precede initiation of statin therapy. Risk 
discussion should include a review of major risk factors 
(e.g., cigarette smoking, high blood pressure, LDL-
cholesterol, hemoglobin A1C (if relevant), and calculated 
10-year CV risk); the presence of risk-enhancing factors 
(Table 2); the potential benefits of lifestyle and statin 
therapies; the potential for adverse effects and drug–drug 
interactions; consideration of costs of statin therapy; and 
patient preferences and values in shared decision-making. 
 
9. In adults 40-75 years of age without DM and with 
LDL-cholesterol levels ≥70 mg/dL, at a 10-year CV risk 
of ≥7.5%, one should start a moderate-intensity statin 
depending on the outcome of the discussion about 
treatment options. Risk-enhancing factors favor statin 
therapy (Table 2). If risk status is uncertain, consider using 
CAC to improve specificity. If statins are indicated, LDL-
cholesterol levels should be reduced by ≥30%, and if 10-
year risk is ≥20%, LDL-cholesterol levels should be 
reduced by ≥50%. 
 
10. In adults 40-75 years of age without DM and 10-
year risk of 7.5-19.9% (intermediate risk), risk-
enhancing factors favor initiation of statin therapy 
(Table 2). Risk-enhancing factors may favor statin therapy 
in patients at 10-year risk of 5-7.5% (borderline risk). 
 
11. In adults 40-75 years of age without DM and with 
LDL-cholesterol levels ≥70 mg/dL to 189 mg/dL, at a 
10-year CVD risk of ≥7.5% to 19.9%, if a decision 
about statin therapy is uncertain, consider measuring 
CAC. If CAC is zero, treatment with statin therapy may be 
withheld or postponed, except in cigarette smokers, those 
with DM, and those with a strong family history of 
premature CVD. A CAC score of 1-99 favors statin 
therapy, especially in those ≥55 years of age. For any 
patient, if the CAC score is ≥100 Agatston units or ≥75th 
percentile, statin therapy is indicated unless otherwise 
decided during the clinician–patient risk discussion. 
 
12. Adherence and percentage response to LDL-
cholesterol–lowering agents and lifestyle changes 
should be assessed with repeat lipid measurement 4-12 
weeks after statin initiation or dose adjustment, 
repeated every 3-12 months as needed. Responses to 
lifestyle and statin therapy should be defined by percentage 
reductions in LDL-cholesterol levels compared with 
baseline. In CVD patients at very high-risk, triggers for 
adding non-statin drug therapy are defined by threshold 
LDL-cholesterol levels ≥70 mg/dL on maximal statin 
therapy. 
 
Table 3. Intensity of statin therapy 
 
● High-intensity statins (>50% LDL-cholesterol lowering) 
Atorvastatin 40-80 mg / Rosuvastatin 20-40 mg 
● Moderate intensity statins (30-50% LDL-cholesterol 
lowering) 
Atorvastatin 10-20 mg / Rosuvastatin 5-10 mg / Simvastatin 20-
40 mg / Pravastatin 40-80 mg / Lovastatin 40-80 mg / Fluvastatin 
XL 80 mg / Fluvastatin 40 mg bid / Pitavastatin 1-4 mg 
● Low-intensity statins (<30% LDL-cholesterol lowering) 
Simvastatin 10 mg / Pravastatin 10-20 mg / Lovastatin 20 mg / 
Fluvastatin 20-40 mg 
 
Risk-Enhancing Factors 
 
A companion report was published simultaneously 
with the cholesterol guidelines and provides guidance 
about the use of quantitative risk assessment in primary 
prevention for CVD.4 The risk calculator that uses several 
variables (Table 1) was introduced in the 2013 guidelines 
and remains an important tool to help health care providers 
identify a patient’s 10-year risk for CVD.5 An additional 
tool to this calculator is provided by the current guidelines, 
a list of “risk-enhancing factors” (Table 2) urging 
physicians to talk with patients about these factors that can 
provide a more personalized approach to a person’s risk, 
in addition to traditional risk factors such as smoking, high 
blood pressure and high blood glucose to address under- or 
over-estimated risk in some individuals. This additional 
information will be helpful in determining what kind of 
treatment plan a person needs. Risk-enhancing factors 
include a positive family history of premature CVD; 
specific racial/ethnic backgrounds; and certain 
comorbidities such as metabolic syndrome, chronic kidney 
disease, chronic inflammatory conditions, premature 
menopause or pre-eclampsia, and certain lipid and other 
biomarkers (Table 2). 
 
Primary and Secondary Prevention 
 
In primary and secondary prevention, when high 
cholesterol cannot be controlled by diet or exercise, the 
first line of treatment is typically statins, mostly available 
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in generic forms and long-documented to safely and 
effectively lower LDL-C levels and CVD risk. 
For secondary prevention in people who have already 
had a myocardial infarction (MI) or stroke and are at 
highest risk for a recurrence and whose LDL-cholesterol 
levels are not adequately lowered by statin therapy, the 
guidelines now recommend the select use of other 
cholesterol-lowing drugs that can be added to a statin 
regimen. The guidelines recommend a graded approach 
with ezetimibe, which is now available as a generic, in 
addition to the statin for these patients. If that combination 
is not sufficiently effective, a PCSK9 inhibitor could be 
added, specifically for people who are at very high risk.6 
This approach may also be considered in primary 
prevention for people who have familial 
hypercholesterolemia. Once treatment is started, whether 
only lifestyle modifications are prescribed or if medication 
therapy is added, adherence and efficacy should be 
assessed at 4-12 weeks with a fasting lipid test, 
subsequently retested every 3-12 months as needed. 
As mentioned, another new aspect of the guidelines is 
the recommendation of coronary artery calcium (CAC) 
measurements for people in some risk categories. A CAC 
score of zero typically indicates a low risk for CVD and 
could mean those people can forego or at least delay 
cholesterol-lowering therapy as long as they are non-
smokers or do not have other high-risk features.  
 
Pediatric Population 
 
Recognizing the cumulative effect of high cholesterol 
over long-term and over the full lifespan of an individual, 
identifying and treating it early can help reduce the lifetime 
risk for CVD. Selective cholesterol testing is appropriate 
for children as young as 2-years old who have a family 
history of heart disease or high cholesterol. As mentioned, 
in most children, an initial test can be considered between 
the ages of 9 and 11 and then again between 17 and 21. 
Because of a lack of sufficient evidence in young adults, 
there are no specific treatment recommendations for that 
age group. However, it is essential that they adhere to a 
healthy lifestyle, be aware of the risk of high cholesterol 
levels and receive therapy as appropriate at all ages to 
reduce the lifetime risk of CVD and stroke. When high 
cholesterol is identified in children (Table 4), that could 
also alert a physician to test other family members who 
may not be aware that they have high cholesterol levels; 
awareness and treatment can save lives. Finally, the 
guidelines offer more specific recommendations for 
certain age and ethnic groups, as well as for people with 
DM, all important for the comprehensive and 
individualized medical provider-patient discussion 
approach. 
 
Table 4. Lipid values in children (mg/dl) 
          Acceptable / Borderline/Abnormal 
Total cholesterol  <170 / 170-200 / >200 
Triglycerides 
 Age 0-9 y  <75 / 75-100 / >100 
 Age 10-19 y  <90 / 90-130 / >130 
HDL cholesterol  >45 / 40-45 / <40  
LDL cholesterol  <110 / 110-130 / >130 
Non-HDL cholesterol   <120 / 120-145 / >145 
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